论文部分内容阅读
为评价氟罗沙星(FLX)的疗效和安全性,以氧氟沙星(OFX)为对照药,在228例细菌性感染病例中进行了随机对照观察,包括尿路感染115例、下呼吸道感染88例和腹腔感染25例。应用 FLX 者115例,OFX 者113例。治疗结果 FLX 和 OFX 组的总有效率分别为83.5%和84.1%,治愈率为67.0%和66.4%;细菌清除率各为85.0%和85.7%。两组的不良反应均轻微,呈一过性,发生率为11.3%(FLX 组)和10.5%(OFX 组),主要为消化道反应。两组差异无显著性。结论:在治疗常见细菌感染时,FLX200～400mg·日~(-1)·次~(-1)与 OFX200～300mg 每日2次,疗程5～14日的治疗方案,其疗效和安全性相仿。
To evaluate the efficacy and safety of fleroxacin (FLX), OFX was used as a randomized controlled trial in 228 bacterial infections including 115 urinary tract infections and 88 lower respiratory tract infections Cases and abdominal infections in 25 cases. There were 115 cases of FLX and 113 cases of OFX. Results The total effective rates of FLX and OFX group were 83.5% and 84.1%, and the cure rates were 67.0% and 66.4% respectively. The bacterial clearance rates were 85.0% and 85.7% respectively. Adverse reactions in both groups were mild, transient, the incidence was 11.3% (FLX group) and 10.5% (OFX group), mainly for gastrointestinal reactions. No significant difference between the two groups. CONCLUSION: In the treatment of common bacterial infections, FLX200 ~ 400mg · day -1 (-1) and OFX200 ~ 300mg twice daily, the course of treatment for 5 to 14 days, the efficacy and safety similar .